466 related articles for article (PubMed ID: 29390896)
1. Targeting the endocannabinoid system as a potential anticancer approach.
Schwarz R; Ramer R; Hinz B
Drug Metab Rev; 2018 Feb; 50(1):26-53. PubMed ID: 29390896
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the Endocannabinoid System as a Potential Anticancer Strategy.
Ramer R; Schwarz R; Hinz B
Front Pharmacol; 2019; 10():430. PubMed ID: 31143113
[TBL] [Abstract][Full Text] [Related]
3. Endocannabinoids and Their Pharmacological Actions.
Pertwee RG
Handb Exp Pharmacol; 2015; 231():1-37. PubMed ID: 26408156
[TBL] [Abstract][Full Text] [Related]
4. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
[TBL] [Abstract][Full Text] [Related]
5. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Desroches J; Charron S; Bouchard JF; Beaulieu P
Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging.
Pascual AC; Gaveglio VL; Giusto NM; Pasquaré SJ
Exp Gerontol; 2014 Jul; 55():134-42. PubMed ID: 24768821
[TBL] [Abstract][Full Text] [Related]
7. Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?
Wilkerson JL; Bilbrey JA; Felix JS; Makriyannis A; McMahon LR
Pharmacol Biochem Behav; 2021 Jul; 206():173192. PubMed ID: 33932409
[TBL] [Abstract][Full Text] [Related]
8. Update on the endocannabinoid system as an anticancer target.
Malfitano AM; Ciaglia E; Gangemi G; Gazzerro P; Laezza C; Bifulco M
Expert Opin Ther Targets; 2011 Mar; 15(3):297-308. PubMed ID: 21244344
[TBL] [Abstract][Full Text] [Related]
9. Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.
Manterola A; Bernal-Chico A; Cipriani R; Canedo-Antelo M; Moreno-García Á; Martín-Fontecha M; Pérez-Cerdá F; Sánchez-Gómez MV; Ortega-Gutiérrez S; Brown JM; Hsu KL; Cravatt B; Matute C; Mato S
Biochem Pharmacol; 2018 Nov; 157():189-201. PubMed ID: 30075103
[TBL] [Abstract][Full Text] [Related]
10. Endocannabinoids in the gastrointestinal tract.
Lee Y; Jo J; Chung HY; Pothoulakis C; Im E
Am J Physiol Gastrointest Liver Physiol; 2016 Oct; 311(4):G655-G666. PubMed ID: 27538961
[TBL] [Abstract][Full Text] [Related]
11. Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease - A Systematic Review.
Hryhorowicz S; Kaczmarek-Ryś M; Zielińska A; Scott RJ; Słomski R; Pławski A
Front Immunol; 2021; 12():790803. PubMed ID: 35003109
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of cannabinoid receptor ligands: current status.
Singh J; Budhiraja S
Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
[TBL] [Abstract][Full Text] [Related]
13. Biological evaluation of pyridone alkaloids on the endocannabinoid system.
Chicca A; Berg R; Jessen HJ; Marck N; Schmid F; Burch P; Gertsch J; Gademann K
Bioorg Med Chem; 2017 Nov; 25(22):6102-6114. PubMed ID: 28284861
[TBL] [Abstract][Full Text] [Related]
14. Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB
Karwad MA; Couch DG; Wright KL; Tufarelli C; Larvin M; Lund J; O'Sullivan SE
Biochem Pharmacol; 2019 Oct; 168():465-472. PubMed ID: 31325449
[TBL] [Abstract][Full Text] [Related]
15. Interaction of ligands for the peroxisome proliferator-activated receptor gamma with the endocannabinoid system.
Lenman A; Fowler CJ
Br J Pharmacol; 2007 Aug; 151(8):1343-51. PubMed ID: 17592505
[TBL] [Abstract][Full Text] [Related]
16. Endocannabinoid System: the Direct and Indirect Involvement in the Memory and Learning Processes-a Short Review.
Kruk-Slomka M; Dzik A; Budzynska B; Biala G
Mol Neurobiol; 2017 Dec; 54(10):8332-8347. PubMed ID: 27924524
[TBL] [Abstract][Full Text] [Related]
17. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.
Di Marzo V
Pharmacol Res; 2009 Aug; 60(2):77-84. PubMed ID: 19559360
[TBL] [Abstract][Full Text] [Related]
18. An introduction to the endocannabinoid system: from the early to the latest concepts.
De Petrocellis L; Di Marzo V
Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):1-15. PubMed ID: 19285257
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.
Celorrio M; Fernández-Suárez D; Rojo-Bustamante E; Echeverry-Alzate V; Ramírez MJ; Hillard CJ; López-Moreno JA; Maldonado R; Oyarzábal J; Franco R; Aymerich MS
Brain Behav Immun; 2016 Oct; 57():94-105. PubMed ID: 27318096
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies.
Janero DR; Vadivel SK; Makriyannis A
Int Rev Psychiatry; 2009 Apr; 21(2):122-33. PubMed ID: 19367506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
